HMGCS2 enhances invasion and metastasis via direct interaction with PPARα to activate Src signaling in colorectal cancer and oral cancer

Oncotarget

Volumn 8, Issue 14, 2017, Pages 22460-22476

  Chen, Shih Wen ^a   Chou, Chiang Ting ^b   Chang, Cheng Chi ^a,c,d,e,f   Li, Yue Ju ^c   Chen, Szu Ta ^c,d   Lin, I Ching ^g,h,i   Kok, Sang Heng ^d   Cheng, Shih Jung ^a,c,d   Lee, Jang Jaer ^e   Wu, Tai Sheng ^c   Kuo, Min Liang ^j   Lin, Been Ren ^d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^j KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

CRC; HMGCS2; Metastasis; OSCC; PPAR

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN TYROSINE KINASE; HMGCS2 PROTEIN, HUMAN; PROTEIN KINASE P60; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; ECTOPIC EXPRESSION; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL MOTION; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MITOCHONDRION; MORTALITY; MOUTH NEOPLASMS; PHYSIOLOGY; PROGNOSIS; SCID MOUSE; SURVIVAL ANALYSIS; TUMOR CELL CULTURE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA SYNTHASE; MICE; MICE, SCID; MITOCHONDRIA; MOUTH NEOPLASMS; PPAR ALPHA; PROGNOSIS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 85016957373     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13006     Document Type: Article

References (29)

1. Boyle P, Macfarlane GJ, Blot WJ, Chiesa F, Lefebvre JL, Azul AM, de Vries N, Scully C. Eur J Cancer B. Oral Oncol. 1995; 31:75-85.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45:309-16.
3. Lin BR, Chang CC, Chen RJ, Jeng YM, Liang JT, Lee PH, Chang KJ, Kuo ML. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res. 2011; 17:3077-88.
4. Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials. BMJ. 2015; 16:350.
5. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27:3677-83.
6. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, Chau YP, Kuo ML. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology. 2005; 128:9-23.
7. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg. 2006; 93:1115-22.
8. Lin BR, Huang MT, Chen ST, Jeng YM, Li YJ, Liang JT, Lee PH, Chang KJ, Chang CC. Prognostic significance of TWEAK expression in colorectal cancer and effect of its inhibition on invasion. Ann Surg Oncol. 2012; 3:385-94.
9. Galbiatti AL, Padovani-Junior JA, Maníglia JV, Rodrigues CD, Pavarino éC, Goloni-Bertollo EM. Head and neck cancer: causes, prevention and treatment. Braz J Otorhinolaryngol. 2013; 79:239-247.
10. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev. 2005; 24:9-17.
11. Jemal A1, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics. CA Cancer J Clin. 2004; 54:8-29.
12. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113:1911-1932.
13. Meijer GA, Hermsen MA, Baak JP, van Diest PJ, Meuwissen SG, Beliën JA, Hoovers JM, Joenje H, Snijders PJ, Walboomers JM. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol. 1998; 51:901-9.
14. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008; 25:2097-116.
15. Bailar JC, Gornik HL, Cancer undefeated. N Engl J Med. 1997; 336:1569-74.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-74.
17. Warburg, O. On the origin of cancer cells. Science. 1956; 123:309-314.
18. Warburg, O. On respiratory impairment in cancer cells. Science. 1956; 124:269-70.
19. Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F. Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle. 2012; 11:3956-63.
20. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, Lisanti MP. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvi-ronment. Int J Biochem Cell Biol. 2011; 43:1045-51.
21. Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K, Diamandis EP. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics. 2013; 12:1589-601.
22. Shafqat N, Turnbull A, Zschocke J, Oppermann U, Yue WW. Crystal structures of human HMG-CoA synthase isoforms provide insights into inherited ketogenesis disorders and inhibitor design. J Mol Biol. 2010; 398:497-506.
23. Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE. FASEB J. 2010; 24:1914-24.
24. Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPAR. EMBO J. 1998; 17:6972-8.
25. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999; 103:1489-98.
26. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 2002; 62:3282-8.
27. Heike Allgayer, Douglas D. Boyd, Markus M. Heiss, Eddie K. Abdalla, Steven A. Curley, Gary E. Gallick. Activation of Src kinase in primary colorectal carcinoma. Cancer. 2002; 94:344-51.
28. Chen JY1, Hung CC, Huang KL, Chen YT, Liu SY, Chiang WF. Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. Neoplasia. 2008; 10:1393-401.
29. Kuruppu D, Christophi C, Bertram JF, O'Brien PE. Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol. 1996; 11:26-32.